Kidney Cancer

Erdafitinib (Brand name: Balversa) is an oral pan-FGFR tyrosine kinase inhibitor used for the treatment of patients with locally advanced or metastatic urothelial carcinoma carrying FGFR2 or FGFR3 genetic alterations, especially in cases where platinum-based chemotherapy has failed.

MedFind provides overseas sourcing services for Erdafitinib through regulated international channels, with full logistics tracking and encrypted privacy protection throughout the process.

Learn more about indications, clinical efficacy, side effects, and medication guidance.